

NC MEDICAID DIVISION OF HEALTH BENEFITS

PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Tuesday, January 13, 2026, 1:00 p.m. – 5:00 p.m. Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter to make proposed changes. Additionally, every PDL category is reviewed at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:

Alzheimer's Agents

1. Alzheimer's Agents

Analgesics

- 1. Orally Disintegrating / Oral Spray Schedule II Opioids
 - a. (Please note this category is being removed from the PDL)
- 2. NSAIDS
- 3. Neuropathic pain

Anticonvulsants

- 1. Carbamazepine Derivatives
- 2. Second Generation

Anti-Infectives – Systemic

- 1. Antibiotics: Lincosamides and Oxazolidinones
- 2. Nitroimidazoles (Gastrointestinal Antibiotics)
- 3. Antivirals (Hepatitis B Agents)
- 4. Antibiotics, Inhaled

Behavioral Health

- 1. Antidepressants (Other)
- 2. Selective Serotonin Reuptake Inhibitor (SSRI)
- 3. Antihyperkinesis / ADHD

Cardiovascular

- 1. Angiotensin II Receptor Blockers
- 2. Beta Blockers
- 3. Direct Renin Inhibitor
- 4. Inhaled Prostacyclin Analogs

- 5. PCSK9
- 6. Platelet Inhibitors

Endocrinology

- 1. Hypoglycemics Injectable Rapid Acting
- 2. Hypoglycemics Short Acting Insulin
- 3. Hypoglycemics Long Acting Insulin
- 4. Hypoglycemics Premixed 70/30 Combination Insulin
- 5. Amylin Analogs
- 6. Alpha-Glucosidase Inhibitors
- 7. Thiazolidinediones and Combinations

Gastrointestinal

- 1. Histamine-2 Receptor Antagonists
- 2. Progestins Used for Cachexia

Hematologic

- 1. Anticoagulants (Oral)
- 2. Thrombopoiesis Stimulating Agents

Osteoporosis

1. Bone Resorption Suppression and Related Agents

Respiratory

- 1. Orally Inhaled Anticholinergics / COPD Agents
- 2. Inhaled Corticosteroids
- 3. First Generation Antihistamines

Topicals

- 1. Acne Agents
- 2. Antifungals

Miscellaneous

- 1. Urea Cycle Disorder Treatments, Oral
- 2. Immunomodulators, Atopic Dermatitis
- 3. Epinephrine, Self-Administered
- 4. Glucocorticoid Steroids, Oral
- 5. Cytokine And Cam Antagonists
- 6. Hereditary Angioedema (HAE) Prophylaxis Agents
- 7. Hereditary Angioedema (HAE) Treatment Agents
- 8. Opioid Antagonists
- 9. Opioid Dependence
- 10. Skeletal Muscle Relaxants

Obsolete Drugs

- 1. Obsolete drugs
- V. Closing comments and adjournment